Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2007, Article ID 90289, 10 pages
http://dx.doi.org/10.1155/2007/90289
Review Article

Peroxisome Proliferator-Activated Receptors in Lung Cancer

1Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI 48109, USA
2Division of Pulmonary, Allergy and Critical Care Medicine, Emory University, School of Medicine, Atlanta, GA 30322, USA
3Atlanta Veterans Affairs Medical Center, Atlanta, GA 30033, USA

Received 11 April 2007; Accepted 3 July 2007

Academic Editor: T. J. Standiford

Copyright © 2007 Venkateshwar G. Keshamouni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. T. Greenlee, T. Murray, S. Bolden, and P. A. Wingo, “Cancer statistics,” A Cancer Journal for Clinicians, vol. 50, pp. 7–33, 2000. View at Google Scholar
  2. Y. Sekido, K. M. Fong, and J. D. Minna, “Progress in understanding the molecular pathogenesis of human lung cancer,” Biochimica et Biophysica Acta—Reviews on Cancer, vol. 1378, no. 1, pp. F21–F59, 1998. View at Publisher · View at Google Scholar
  3. S. Han and J. Roman, “Peroxisome proliferators-activated receptor gamma: a novel target for cancer therapeutics?” Anticancer Drugs, vol. 18, pp. 237–244, 2007. View at Google Scholar
  4. M. Robinson-Rechavi, A. S. Carpentier, M. Duffraisse, and V. Laudet, “How many nuclear hormone receptors are there in the human genome?” Trends in Genetics, vol. 17, no. 10, pp. 554–556, 2001. View at Publisher · View at Google Scholar
  5. H. Laudet VaG, The Nuclear Receptor Facts Book, Academic Press, San Diego, Calif, USA, 2002.
  6. J. Auwerx, E. Baulieu, M. Beato et al., “A unified nomenclature system for the nuclear receptor superfamily,” Cell, vol. 97, no. 2, pp. 161–163, 1999. View at Publisher · View at Google Scholar
  7. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar · View at PubMed
  8. L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome-proliferator-activated receptors and cancers: complex stories,” Nature Reviews Cancer, vol. 4, no. 1, pp. 61–70, 2004. View at Publisher · View at Google Scholar · View at PubMed
  9. P. Delerive, K. De Bosscher, S. Besnard et al., “Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NfκB and AP-1,” The Journal of Biological Chemistry, vol. 274, no. 45, pp. 32048–32054, 1999. View at Publisher · View at Google Scholar
  10. N. Wang, L. Verna, N. G. Chen et al., “Constitutive activation of peroxisome proliferator-activated receptor-γ suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells,” The Journal of Biological Chemistry, vol. 277, no. 37, pp. 34176–34181, 2002. View at Publisher · View at Google Scholar · View at PubMed
  11. Y. Shi, M. Hon, and R. M. Evans, “The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 5, pp. 2613–2618, 2002. View at Publisher · View at Google Scholar · View at PubMed
  12. J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,” Progress in Lipid Research, vol. 45, no. 2, pp. 120–159, 2006. View at Publisher · View at Google Scholar · View at PubMed
  13. H. Kawamata, M. Tachibana, T. Fujimori, and Y. Imai, “Differentiation-inducing therapy for solid tumors,” Current Pharmaceutical Design, vol. 12, no. 3, pp. 379–385, 2006. View at Publisher · View at Google Scholar
  14. R. P. Warrell Jr., S. R. Frankel, W. H. Miller Jr. et al., “Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid),” The New England Journal of Medicine, vol. 324, no. 20, pp. 1385–1393, 1991. View at Google Scholar
  15. D. J. Kim, M. T. Bility, A. N. Billin, T. M. Willson, E. J. Gonzalez, and J. M. Peters, “PPARβ/δ selectively induces differentiation and inhibits cell proliferation,” Cell Death Differentiation, vol. 13, pp. 53–60, 2006. View at Publisher · View at Google Scholar · View at PubMed
  16. N. S. Tan, N. Vinckenbosch, P. Liu et al., “Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription,” Molecular and Cellular Biology, vol. 22, no. 14, pp. 5114–5127, 2002. View at Publisher · View at Google Scholar
  17. Q. Yan, S. Ito, and F. J. Gonzalez, “Hepatocyte-restricted constitutive activation of PPARα induces hepatoproliferation but not hepatocarcinogenesis,” Carcinogenesis, vol. 28, no. 6, pp. 1171–1177, 2007. View at Publisher · View at Google Scholar · View at PubMed
  18. E. A. Lock, A. M. Mitchell, and C. R. Elcombe, “Biochemical mechanisms of induction of hepatic peroxisome proliferation,” Annual Review of Pharmacology and Toxicology, vol. 29, pp. 145–163, 1989. View at Publisher · View at Google Scholar · View at PubMed
  19. D. Auboeuf, J. Rieusset, L. Fajas et al., “Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver x receptor-alpha in humans: no alteration in adipose tissue of obese and niddm patients,” Diabetes, vol. 46, no. 8, pp. 1319–1327, 1997. View at Publisher · View at Google Scholar
  20. O. Braissant, F. Foufelle, C. Scotto, M. Dauca, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat,” Endocrinology, vol. 137, pp. 354–366, 1996. View at Publisher · View at Google Scholar
  21. Q. N. Diep, R. M. Touyz, and E. L. Schiffrine, “Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase,” Hypertension, vol. 36, no. 5, pp. 851–855, 2000. View at Google Scholar
  22. I. Inoue, K. Shino, S. Noji, T. Awata, and S. Katayama, “Expression of peroxisome proliferator-activated receptor alpha (ppar alpha) in primary cultures of human vascular endothelial cells,” Biochemical and Biophysical Research Communications, vol. 246, no. 2, pp. 370–374, 1998. View at Publisher · View at Google Scholar · View at PubMed
  23. G. Chinetti, S. Griglio, M. Antonucci et al., “Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages,” The Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998. View at Publisher · View at Google Scholar
  24. S. S. Lee, T. Pineau, J. Drago et al., “Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators,” Molecular and Cellular Biology, vol. 15, no. 6, pp. 3012–3022, 1995. View at Google Scholar
  25. J. M. Peters, T. Aoyama, R. C. Cattley, U. Nobumitsu, T. Hashimoto, and F. J. Gonzalez, “Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver,” Carcinogenesis, vol. 19, no. 11, pp. 1989–1994, 1998. View at Publisher · View at Google Scholar
  26. J. M. Peters, R. C. Cattley, and F. J. Gonzalez, “Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator wy-14,643,” Carcinogenesis, vol. 18, no. 11, pp. 2029–2033, 1997. View at Publisher · View at Google Scholar
  27. A. C. Bayly, R. A. Roberts, and C. Dive, “Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin,” The Journal of Cell Biology, vol. 125, no. 1, pp. 197–203, 1994. View at Publisher · View at Google Scholar
  28. R. A. Roberts, “Non-genotoxic hepatocarcinogenesis: suppression of apoptosis by peroxisome proliferators,” Annals of the New York Academy of Sciences, vol. 804, no. 1, pp. 588–611, 1996. View at Publisher · View at Google Scholar
  29. R. A. Roberts, N. H. James, N. J. Woodyatt, N. Macdonald, and J. D. Tugwood, “Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha),” Carcinogenesis, vol. 19, no. 1, pp. 43–48, 1998. View at Publisher · View at Google Scholar
  30. P. Bentley, I. Calder, C. Elcombe, P. Grasso, D. Stringer, and H. J. Wiegand, “Hepatic peroxisome proliferation in rodents and its significance for humans,” Food and Chemical Toxicology, vol. 31, no. 11, pp. 857–907, 1993. View at Publisher · View at Google Scholar
  31. E. Boitier, J. C. Gautier, and R. Roberts, “Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease,” Comparative Hepatology, vol. 2, no. 1, p. 3, 2003. View at Publisher · View at Google Scholar
  32. C. Scotto, J. M. Keller, H. Schohn, and M. Dauca, “Comparative effects of clofibrate on peroxisomal enzymes of human (hep ebna2) and rat (fao) hepatoma cell lines,” European Journal of Cell Biology, vol. 66, no. 4, pp. 375–381, 1995. View at Google Scholar
  33. C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli, “Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors,” Cell, vol. 68, no. 5, pp. 879–887, 1992. View at Publisher · View at Google Scholar
  34. S. A. Kliewer, B. M. Forman, B. Blumberg et al., “Differential expression and activation of a family of murine peroxisome proliferator-activated receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, pp. 7355–7359, 1994. View at Publisher · View at Google Scholar
  35. E. Z. Amri, F. Bonino, G. Ailhaud, N. A. Abumrad, and P. A. Grimaldi, “Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors,” The Journal of Biological Chemistry, vol. 270, no. 5, pp. 2367–2371, 1995. View at Publisher · View at Google Scholar
  36. L. Jow and R. Mukherjee, “The human peroxisome proliferator-activated receptor (PPAR) subtype nuc1 represses the activation of hppar alpha and thyroid hormone receptors,” Journal of Biological Chemistry, vol. 270, no. 8, pp. 3836–3840, 1995. View at Publisher · View at Google Scholar
  37. H. Matsuo and J. F. Strauss III, “Peroxisome proliferators and retinoids affect JEG-3 choriocarcinoma cell function,” Endocrinology, vol. 135, no. 3, pp. 1135–1145, 1994. View at Publisher · View at Google Scholar
  38. J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002. View at Publisher · View at Google Scholar · View at PubMed
  39. M. L. Sznaidman, C. D. Haffner, P. R. Maloney et al., “Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPAR-delta)—synthesis and biological activity,” Bioorganic & Medicinal Chemistry Letters, vol. 13, no. 9, pp. 1517–1521, 2003. View at Publisher · View at Google Scholar
  40. C. E. Bassene, F. Suzenet, N. Hennuyer et al., “Studies towards the conception of new selective PPAR beta/delta ligands,” Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 17, pp. 4528–4532, 2006. View at Publisher · View at Google Scholar · View at PubMed
  41. R. Epple, M. Azimioara, R. Russo et al., “1,3,5-trisubstituted aryls as highly selective PPARdelta agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 11, pp. 2969–2973, 2006. View at Publisher · View at Google Scholar · View at PubMed
  42. Y. Barak, D. Liao, W. He et al., “Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 1, pp. 303–308, 2002. View at Publisher · View at Google Scholar · View at PubMed
  43. J. M. Peters, S. S. Lee, W. Li et al., “Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta),” Molecular and Cellular Biology, vol. 20, no. 14, pp. 5119–5128, 2000. View at Publisher · View at Google Scholar
  44. N. S. Tan, L. Michalik, N. Noy et al., “Critical roles of ppar beta/delta in keratinocyte response to inflammation,” Genes & Development, vol. 15, no. 24, pp. 3263–3277, 2001. View at Publisher · View at Google Scholar · View at PubMed
  45. G. D. Barish., V. A. Narkar, and R. M. Evans, “Ppar delta: a dagger in the heart of the metabolic syndrome,” The Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006. View at Publisher · View at Google Scholar · View at PubMed
  46. A. D. Burdick, D. J. Kim, M. A. Peraza, F. J. Gonzalez, and J. M. Peters, “The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation ,” Cellular Signalling, vol. 18, no. 1, pp. 9–20, 2006. View at Publisher · View at Google Scholar · View at PubMed
  47. S. Han, J. D. Ritzenthaler, B. Wingerd, and J. Roman, “Activation of peroxisome proliferator-activated receptor beta/delta (PPARβ/δ) increases the expression of prostaglandin E2 receptor subtype E4. The role of phosphatidylinositol 3-kinase and CCAAAT/enhancer-binding protein beta,” The Journal of Biological Chemistry, vol. 280, no. 39, pp. 33240–33249, 2005. View at Publisher · View at Google Scholar · View at PubMed
  48. L. Fajas, D. Auboeuf, E. Raspe et al., “The organization, promoter analysis, and expression of the human ppargamma gene,” The Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997. View at Publisher · View at Google Scholar
  49. L. Fajas, J. C. Fruchart, and J. Auwerx, “PPAR-gamma3 mRNA: a distinct PPAR-gamma mRNA subtype transcribed from an independent promoter,” FEBS Letters, vol. 438, no. 1-2, pp. 55–60, 1998. View at Publisher · View at Google Scholar
  50. B. M. Spiegelman, “Ppar-gamma: adipogenic regulator and thiazolidinedione receptor,” Diabetes, vol. 47, no. 4, pp. 507–514, 1998. View at Publisher · View at Google Scholar
  51. P. Tontonoz, E. Hu, and B. M. Spiegelman, “Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor,” Cell, vol. 79, no. 7, pp. 1147–1156, 1994. View at Publisher · View at Google Scholar
  52. M. Lehrke and M. A. Lazar, “The many faces of PPAR gamma,” Cell, vol. 123, no. 6, pp. 993–999, 2005. View at Publisher · View at Google Scholar · View at PubMed
  53. R. K. Semple, V. K. Chatterjee, and S. O'Rahilly, “PPAR γ and human metabolic disease,” Journal of Clinical Investigation, vol. 116, pp. 581–589, 2006. View at Publisher · View at Google Scholar · View at PubMed
  54. T. J. Standiford, V. G. Keshamouni, and R. C. Reddy, “Peroxisome proliferator-activated receptor-γ as a regulator of lung inflammation and repair,” Proceedings of the American Thoracic Society, vol. 2, no. 3, pp. 226–231, 2005. View at Publisher · View at Google Scholar · View at PubMed
  55. E. Elstner, C. Muller, K. Koshizuka et al., “Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 15, pp. 8806–8811, 1998. View at Publisher · View at Google Scholar
  56. K. G. Lambe and J. D. Tugwood, “A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs,” European Journal of Biochemistry / FEBS, vol. 239, no. 1, pp. 1–7, 1996. View at Publisher · View at Google Scholar
  57. E. Mueller, P. Sarraf, P. Tontonoz et al., “Terminal differentiation of human breast cancer through PPAR gamma,” Molecular Cell, vol. 1, no. 3, pp. 465–470, 1998. View at Publisher · View at Google Scholar
  58. P. Sarraf, E. Mueller, D. Jones et al., “Differentiation and reversal of malignant changes in colon cancer through PPAR gamma,” Nature Medicine, vol. 4, pp. 1046–1052, 1998. View at Publisher · View at Google Scholar · View at PubMed
  59. R. A. Daynes and D. C. Jones, “Emerging roles of PPARs in inflammation and immunity,” Nature Reviews Immunology, vol. 2, no. 10, pp. 748–759, 2002. View at Publisher · View at Google Scholar · View at PubMed
  60. C. Jiang, A. T. Ting, and B. Seed, “PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Google Scholar
  61. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Google Scholar
  62. V. G. Keshamouni, R. C. Reddy, D. A. Arenberg et al., “Peroxisome proliferator activated receptor gamma activation inhibits tumor progression in non small cell lung cancer,” Oncogene, vol. 23, no. 1, pp. 100–108, 2004. View at Publisher · View at Google Scholar · View at PubMed
  63. D. Panigrahy, S. Singer, L. Q. Shen et al., “PPAR γ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis,” The Journal of Clinical Investigation, vol. 110, no. 7, pp. 923–932, 2002. View at Publisher · View at Google Scholar
  64. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma),” The Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995. View at Google Scholar
  65. P. B. Watkins and R. W. Whitcomb, “Hepatic dysfunction associated with troglitazone,” The New England Journal of Medicine, vol. 338, no. 13, pp. 916–917, 1998. View at Publisher · View at Google Scholar · View at PubMed
  66. T. Shibata, K. Matsui, K. Nagao, H. Shinkai, F. Yonemori, and K. Wakitani, “Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative,” European Journal of Pharmacology, vol. 364, no. 2-3, pp. 211–219, 1999. View at Publisher · View at Google Scholar
  67. N. Suh, Y. Wang, C. R. Williams et al., “A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis,” Cancer Research, vol. 59, no. 22, pp. 5671–5673, 1999. View at Google Scholar
  68. J. T. Huang, J. S. Welch, M. Ricote et al., “Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase,” Nature, vol. 400, no. 6742, pp. 378–382, 1999. View at Publisher · View at Google Scholar · View at PubMed
  69. L. Nagy, P. Tontonoz, J. G. Alvarez, H. Chen, and R. M. Evans, “Oxidized ldl regulates macrophage gene expression through ligand activation of PPARgamma,” Cell, vol. 93, no. 2, pp. 229–240, 1998. View at Publisher · View at Google Scholar
  70. F. J. Schopfer, Y. Lin, P. R. Baker et al., “Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor γ ligand,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 7, pp. 2340–2345, 2005. View at Publisher · View at Google Scholar · View at PubMed
  71. P. R. Baker, Y. Lin, F. J. Schopfer et al., “Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands,” Journal of Biological Chemistry, vol. 280, no. 51, pp. 42464–42475, 2005. View at Publisher · View at Google Scholar · View at PubMed
  72. B. Y. Hwang, J.-H. Lee, J. B. Nam, H. S. Kim, Y. S. Hong, and J. J. Lee, “Two new furanoditerpenes from Saururus chinenesis and their effects on the activation of peroxisome proliferator-activated receptor γ,” Journal of Natural Products, vol. 65, no. 4, pp. 616–617, 2002. View at Publisher · View at Google Scholar
  73. Y.-C. Liang, S.-H. Tsai, D.-C. Tsai, S.-Y. Lin-Shiau, and J.-K. Lin, “Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-γ by flavonoids in mouse macrophages,” FEBS Letters, vol. 496, no. 1, pp. 12–18, 2001. View at Publisher · View at Google Scholar
  74. M. Kuroda, Y. Mimaki, Y. Sashida et al., “Phenolics with PPAR-gamma ligand-binding activity obtained from licorice (glycyrrhiza uralensis roots) and ameliorative effects of glycyrin on genetically diabetic kk-Ay mice,” Bioorganic & Medicinal Chemistry Letters, vol. 13, no. 24, pp. 4267–4272, 2003. View at Publisher · View at Google Scholar
  75. J. Xu, Y. Fu, and A. Chen, “Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth,” American Journal of Physiology, vol. 285, no. 1, pp. G20–G30, 2003. View at Google Scholar
  76. S. Zheng and A. Chen, “Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro,” The Biochemical Journal, vol. 384, pt. 1, pp. 149–157, 2004. View at Google Scholar
  77. M. J. Reginato, S. T. Bailey, S. L. Krakow et al., “A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties,” Journal of Biological Chemistry, vol. 273, no. 49, pp. 32679–32684, 1998. View at Publisher · View at Google Scholar
  78. K. Inoue, Y. Kawahito, Y. Tsubouchi et al., “Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer,” Anticancer Research, vol. 21, pp. 2471–2476, 2001. View at Google Scholar
  79. T. Satoh, M. Toyoda, H. Hoshino et al., “Activation of peroxisome proliferator-activated receptor-γ stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells,” Oncogene, vol. 21, no. 14, pp. 2171–2180, 2002. View at Publisher · View at Google Scholar · View at PubMed
  80. E. Burgermeister, D. Chuderland, T. Hanoch, M. Meyer, M. Liscovitch, and R. Seger, “Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor γ,” Molecular and Cellular Biology, vol. 27, no. 3, pp. 803–817, 2007. View at Publisher · View at Google Scholar · View at PubMed
  81. M. Li, T. W. Lee, A. P. Yim, T. S. Mok, and G. G. Chen, “Apopotsis induced by troglitazone is both peroxisome proliferator-activated receptor-γ- and ERK-dependent in human non-small cell lung cancer cells,” The Journal of Cell Physiology, vol. 209, no. 2, pp. 428–438, 2006. View at Publisher · View at Google Scholar · View at PubMed
  82. M. Li, T. W. Lee, T. S. Mok, T. D. Warner, A. P. Yim, and G. G. Chen, “Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth,” The Journal of Cellular Biochemistry, vol. 96, no. 4, pp. 760–774, 2005. View at Google Scholar
  83. W. Zou, X. Liu, P. Yue, F. R. Khuri, and S. Y. Sun, “PPARg ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells,” Cancer Biological Therapeutics, vol. 6, no. 1, pp. 99–106, 2007. View at Google Scholar
  84. S. Han, N. Sidell, P. B. Fisher, and J. Roman, “Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells,” Clinical Cancer Research, vol. 10, no. 6, pp. 1911–1919, 2004. View at Publisher · View at Google Scholar
  85. W. Zhang, H. Zhang, and L. Xing, “Influence of ciglitazone on A549 cells growth in vitro and in vivo and mechanism,” Journal of Huazhong University of Science and Technology. Medical Sciences, vol. 26, no. 1, pp. 36–39, 2006. View at Google Scholar
  86. S. V. Fulzele, A. Chatterjee, M. S. Shaik, T. Jackson, N. Ichite, and M. Singh, “15-deoxy-detal 12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non small cell lines and xenograft tumors,” Anticancer Drugs, vol. 18, pp. 65–78, 2007. View at Google Scholar
  87. S. Han and J. Roman, “Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways,” Molecular Cancer Therapeutics, vol. 5, pp. 430–437, 2006. View at Publisher · View at Google Scholar · View at PubMed
  88. S. Lee, G. Y. Hur, K. H. Jung et al., “PPAR-gamma agonist increase gefitinib's antitumor activity thorugh PTEN expression,” Lung Cancer, vol. 51, no. 3, pp. 297–301, 2006. View at Publisher · View at Google Scholar · View at PubMed
  89. J. M. Hall and D. P. McDonnell, “The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages,” Molecular Endocrinology, vol. 21, no. 8, pp. 1756–1768, 2007. View at Publisher · View at Google Scholar · View at PubMed
  90. S. Han and J. Roman, “Suppression of prostaglandin E2 receptor subtype EP2 by PPAR-γ ligands inhibits human lung carcinoma cell growth,” Biochemical and Biophysical Research Communications, vol. 314, no. 4, pp. 1093–1099, 2004. View at Publisher · View at Google Scholar
  91. A. H. Limper and J. Roman, “Fibronectin: a versatile matrix protein with roles in thoracic development, repair and infection,” Chest, vol. 101, no. 6, pp. 1663–1673, 1992. View at Google Scholar
  92. J. Roman, J. D. Ritzenthaler, A. Gil-Acosta, H. N. Rivera, and S. Roser-Page, “Nicotine and fibronectin, expression in lung fibroblasts: implications for tobacco-related lung tissue remodeling,” FASEB Journal, vol. 18, no. 12, pp. 1436–1438, 2004. View at Publisher · View at Google Scholar · View at PubMed
  93. S. Han, F. R. Khuri, and J. Roman, “Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways,” Cancer Research, vol. 66, no. 1, pp. 315–323, 2006. View at Publisher · View at Google Scholar · View at PubMed
  94. S. Han, J. D. Ritzenthaler, S. V. Sitaraman, and J. Roman, “Fibronectin increases matrix metalloproteinase-9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells,” Journal of Biological Chemistry, vol. 281, no. 40, pp. 29614–29624, 2006. View at Publisher · View at Google Scholar · View at PubMed
  95. S. Han, J. D. Ritzenthaler, H. N. Rivera, and J. Roman, “Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1,” American Journal of Physiology (Lung Cellular Molecular Physiology), vol. 289, no. 3, pp. L419–L428, 2005. View at Google Scholar
  96. S. Han, H. N. Rivera, and J. Roman, “Peroxisome proliferator-activated receptor-gamma ligands inhibit alpha5 integrin gene transcription in non-small cell lung carcinoma cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 32, no. 4, pp. 350–359, 2005. View at Publisher · View at Google Scholar · View at PubMed
  97. V. G. Keshamouni, D. A. Arenberg, R. C. Reddy, M. J. Newstead, S. Anthwal, and T. J. Standiford, “PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer,” Neoplasia, vol. 7, no. 3, pp. 294–301, 2005. View at Google Scholar
  98. D. Panigrahy, S. Huang, M. W. Kieran, and A. Kaipainen, “PPARgamma as a therapeutic target for tumor angiogenesis and metastasis,” Cancer Biology Therapeutics, vol. 4, pp. 687–693, 2005. View at Google Scholar
  99. A. K. Ghosh, S. Bhattacharyya, G. Lakos., S. J. Chen., Y. Mori, and J. Varga, “Disruption of transforming growth factor β signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor γ,” Arthritis & Rheumatism, vol. 50, no. 4, pp. 1305–1318, 2004. View at Publisher · View at Google Scholar · View at PubMed
  100. S. Zafiriou, S. R. Stanners, S. Saad, T. S. Polhill, P. Poronnik, and C. A. Pollock, “Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts,” Journal of the American Society of Nephorology, vol. 16, pp. 638–645, 2005. View at Publisher · View at Google Scholar · View at PubMed
  101. H. A. Burgess, L. E. Daugherty, T. H. Thatcher et al., “PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis,” American Journal of Physiology (Lung Cellular Molecular Physiology), vol. 288, pp. L1146–L1153, 2005. View at Google Scholar
  102. L. Yang, C. C. Chan, O. S. Kwon et al., “Regulation of peroxisome proliferator-activated receptor-γ in liver fibrosis,” American Journal of Physiology (Gastrointestinal and Liver Physiology), vol. 291, pp. G902–G911, 2006. View at Publisher · View at Google Scholar · View at PubMed
  103. J. A. Van Ginderachter, S. Meerschaut, Y. Liu et al., “Peroxisome proliferator-activated receptor γ (PPARγ) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer,” Blood, vol. 15, no. 2, pp. 525–535, 2006. View at Publisher · View at Google Scholar · View at PubMed
  104. S. Theocharis, H. Kanelli, E. Politi et al., “Expression of peroxisome proliferator-activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade,” Lung Cancer, vol. 36, no. 3, pp. 249–255, 2002. View at Publisher · View at Google Scholar
  105. G. Muzio, A. Trombetta, M. Maggiora et al., “Arachidonic acid suppresses growth of human lung tumor A549 cells through down-regulation of ALDH3A1 expression,” Free Radicals in Biological Medicine, vol. 40, no. 11, pp. 1929–1938, 2006. View at Publisher · View at Google Scholar · View at PubMed
  106. I. Avis, A. Martinez, J. Tauler et al., “Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition,” Cancer Research, vol. 65, pp. 4181–4190, 2005. View at Publisher · View at Google Scholar · View at PubMed
  107. C. J. Yao, G. M. Lai, C. F. Chan, A. L. Chen, Y. Y. Yang, and S. E. Chuang, “Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone,” International Journal of Cancer, vol. 118, no. 3, pp. 773–779, 2005. View at Publisher · View at Google Scholar · View at PubMed
  108. R. A. Nemenoff and R. A. Winn, “Role of nuclear receptors in lung tumorigenesis,” European Journal of Cancer, vol. 41, no. 16, pp. 2561–2568, 2005. View at Publisher · View at Google Scholar · View at PubMed
  109. R. Govindarajan, L. Ratnasinghe, D. L. Simmons et al., “Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1476–1481, 2007. View at Publisher · View at Google Scholar · View at PubMed
  110. C. D. Allred and M. W. Kilgore, “Selective activation of PPAR γ in breast, colon and lung cancer cell lines,” Molecular and Cellular Endocrinology, vol. 235, no. 1-2, pp. 21–29, 2005. View at Publisher · View at Google Scholar · View at PubMed